| Species |
Human |
| Protein Construction |
OSMR beta-GPL fusion (Met1-Ala428 (OSMR beta) and Leu21-Glu225 (GPL))_x000D_
Accession # Q99650-1(OSMR beta)&Q8NI17-1(GPL) |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized OSMR beta-GPL fusion, His, Human at 1μg/ml (100μl/well) on the plate can bind Anti?OSMR Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
75.84 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 110-140 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
OSMR involvement, together with Gp130-like receptor (GPL), also known as IL-31R, in the formation of a functional IL-31 receptor complex. OSMR-GPL fusion protein was designed to contain the domains of OSMR and GPL required for high affinity IL-31 binding. |
| Synonyms |
OSMR-GPL |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
